Patents by Inventor Roland Jahns
Roland Jahns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9062095Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-?-adrenergic receptor antibodies like anti-?-adrenergic receptor antibodies.Type: GrantFiled: August 22, 2008Date of Patent: June 23, 2015Assignee: JULIUS-MAXIMILIANS-UNIVERSTITAT-WURZBURGInventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Viacheslav Nikolaev
-
Publication number: 20150038673Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-.beta.-adrenergic receptor antibodies like anti-?1-adrenergic receptor antibodies.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Inventors: Roland Jahns, Valerie Jahns, Martin Lohse, Viacheslav Nikolaev
-
Publication number: 20140273015Abstract: The present disclosure relates to binding compounds/antibodies that bind to the second extracellular loop of the human ?1-adrenoreceptor (?1-AR-ECII) that are produced by/obtainable from a host cell/hybridoma with a deposit number selected from the group consisting of DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 and DSM AC-C3177. The binding compounds/antibodies are particularly useful in determination of auto-anti-?1-AR antibodies in an in vitro cell based assay system in order to characterize and to identify auto-antibodies directed against the ?1-AR-ECII in a biological sample. Further aspects of the disclosure are nucleic acid molecules encoding said binding compounds/antibodies, vectors, host cells, methods for producing the binding compounds/antibodies of the disclosure as well as a kit comprising the binding compounds/antibodies of the present disclosure.Type: ApplicationFiled: June 6, 2012Publication date: September 18, 2014Applicant: CORIM- MUN GMBHInventors: Hans-Peter Holthoff, Martin Ungerer, Stefan Zeibig, Martin J. Lohse, Roland Jahns, Valerie Jahns
-
Patent number: 8715682Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: GrantFiled: April 18, 2012Date of Patent: May 6, 2014Assignee: Julius-Mazimillians-Universitat Wurzburg, a German UniversityInventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
-
Patent number: 8716030Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: GrantFiled: April 18, 2012Date of Patent: May 6, 2014Assignee: Julius-Maximillians-Universitat Wurzburg, A Germany UniversityInventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
-
Publication number: 20120288513Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: ApplicationFiled: April 18, 2012Publication date: November 15, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Roland JAHNS, Valérie JAHNS, Martin J. LOHSE, Dieter PALM
-
Publication number: 20120288870Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: ApplicationFiled: April 18, 2012Publication date: November 15, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Roland JAHNS, Valérie JAHNS, Martin J. LOHSE, Dieter PALM
-
Patent number: 8187605Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.Type: GrantFiled: March 31, 2006Date of Patent: May 29, 2012Assignee: Julius-Maximillians-Universität WürzburgInventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
-
Publication number: 20100241901Abstract: Industrial systems (2) have complex process control systems with many degrees of freedom for parameterization. To find faults during the parameterization, the invention proposes a method for checking a control program (12) in order to control an industrial system (2), in which data of the control program (12) is read into a database (20) and a test routine (24) checks the control program (12), on the basis of data, for compliance with defined rules and displays rule infringements.Type: ApplicationFiled: February 10, 2010Publication date: September 23, 2010Inventor: Roland Jahn
-
Publication number: 20100209445Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-?-adrenergic receptor antibodies like anti-?radrenergic receptor antibodies.Type: ApplicationFiled: August 22, 2008Publication date: August 19, 2010Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Viacheslav Nikolaev
-
Publication number: 20090215675Abstract: The present invention is related to a peptide selected from the group comprising a) a cyclic peptide of formula (I): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-x-x-x-Pro-x-Cys-Cys-xk-GIn), (I) whereby k is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably k=6; b) a cyclic peptide of formula (II): Cyclo(Ala-x-x-Trp-x-x-Gly-x-Phe-x-Cys-xh-Gln), (II) whereby h is any integer from 0 to 2, preferably 1 or 2; c) a cyclic peptide of formula (III): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-xj-Cys-x-x-x-Pro-x-Cys-Cys-xi-Gln); (HI) whereby j is any integer from 0 to 4, preferably j=4; whereby i is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably i?6; and d) a peptide of formula (IV): Ala-x1-Cys-xm-Cys-x-x-x-Pro-x-Cys-Cys-xn-Gln, (IV) whereby 1 is any integer from 0 to 9, preferably any integer from 1 to 9, more preferably n=9; whereby m is any integer from 0 to 4, preferably any integer from 1 to 4, more preferably m=4; whereby n is any integer from O to 6, preferably any integer fromType: ApplicationFiled: March 31, 2006Publication date: August 27, 2009Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WURZBURGInventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm